News

COVID-19

Penington Institute is responding to the unfolding COVID-19/coronavirus outbreak by creating a series of informational resources for people who use drugs, their family and friends, and the sector. These resources are designed to provide clear and practical advice. Read more

2020-03-19T14:40:06+11:00March 19th, 2020|

Overdose and Response in Victoria – Seminar

Frontline initiatives to prevent fatal overdose in Victoria Deaths from unintentional overdose are growing. These deaths are, by definition, preventable. However, there are no silver bullets – sophisticated and evidence-based responses are needed to reduce the toll of unintentional overdose. This seminar will provide a brief overview of unintentional overdose deaths in Victoria before discussing three responses: Victoria’s Real-Time Prescription [...]

2020-01-31T12:07:33+11:00October 18th, 2019|

Life Savers global launch exposes opioid treatment

Penington Institute, the not-for-profit convenor of International Overdose Awareness Day, is today launching the website, Life Savers,1 a brief guide to treatment for people concerned about their usage of opioid drugs, their family members and friends, as well as a resource for healthcare providers. As the number of people developing dependencies and suffering harms from opioids increases, so too does [...]

2019-10-10T22:08:51+11:00September 1st, 2019|

Australia’s annual overdose report 2019 released

The toll of unintentional overdose deaths in Australia: Penington Institute Australia’s Annual Overdose Report 2019 reveals that unintentional overdose continues to be a significant cause of death in Australia. The continued growth in unintentional overdose deaths is linked to highly potent drugs, many of which are available through prescription, such as pharmaceutical opioids and benzodiazepines. Illegal drugs such as heroin and stimulants [...]

2020-04-17T11:12:51+10:00August 26th, 2019|

Penington Institute calls for strong action on pregabalin (Lyrica®)

Lyrica®: Filling a pain fap or emerging threat? Penington institute recently hosted a public information forum with experts speakers discussing pregabalin (sold as Lyrica®). Subsidised as an antiepileptic and to treat neuropathic pain, prescriptions rates have increased dramatically in recent years, along with reports of harms relating to use. Dr Shaun Greene (Austin Health) Dr Rose Crossin (Penington Institute) and [...]

2019-06-14T00:01:24+10:00June 14th, 2019|

Australia’s dependence on prescription opioids should be new government’s top public health concern

One of the most urgent public health issues facing the new government will be Australia’s dependence on prescription opioids, independent drug research, policy and education organisation Melbourne-based Penington Institute, said today. Figures just released by the London-based Global Survey on Drugs show that the use of prescription opioids in the last year was highest in Australia (30%) – exceeding both [...]

2019-05-20T17:59:58+10:00May 20th, 2019|

Lyrica®: Filling a pain gap or emerging threat?

Use of pregabalin (sold as Lyrica®) has skyrocketed in recent years. Anecdotal reports indicate problematic use is becoming more common including amongst people who inject drugs. In Australia, pregabalin is a commonly prescribed medicine, subsidised as an anti-epileptic and to treat neuropathic pain. It is often prescribed for the treatment of other conditions including musculoskeletal pain and generalised anxiety disorder. [...]

2019-05-17T13:51:46+10:00May 17th, 2019|

Penington Institute reflects on the achievements of former PM Bob Hawke

Leading independent drug research, policy and education organisation, Penington Institute, has today celebrated the public health achievements of Australia’s 23rd Prime Minister the Hon RJL Hawke AC GCL on the occasion of his passing. Penington Institute CEO John Ryan said that Bob Hawke can be thanked for many aspects of the health of Australians today. “Bob Hawke and his governments [...]

2019-05-17T13:46:09+10:00May 17th, 2019|